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INTRODUCTION
Cyclosporin A is an immune-suppressive drug used in pa-
tients with immune-mediated diseases, chronic diseases re-
quiring organ transplantation, or malignancy. These diseases
often require higher cyclosporin A doses, which may cause
central nervous system (CNS) problems (1-3). Seizures fre-
quently poses a physical threat to patients, who often suffer
from pain requiring appropriate control. Fentanyl is a com-
monly used analgesic agent that is used in that situation.
However, interactions between fentanyl and cyclosporin A,
especially in the CNS, must be considered. Although cyclo-
sporin A-induced neurotoxicity is well recognized, the exact
mechanism is still unclear. Cyclosporin A neurotoxicity may
be due to the effect of cyclosporin A per se or to the combined
effect of cyclosporin A and other associated clinical conditions,
such as hypomagnesemia, hypocalcemia, the effect of multiple
high-dose drugs already administered, antihypertensives, anal-
gesics, steroid, CNS infarct, CNS hemorrhage, CNS vascu-
lar injury, brain ischemia, CNS hypoxia, CNS infection, and
cardiopulmonary dysfunction. 
Moreover, only 28.5% patients experiencing a neurological
complication during cyclosporin A administration showed
the cyclosporin A and its metabolites in the cerebrospinal
fluid (CSF) (4). Therefore, the main question to be answered
is whether cyclosporin A neurotoxicity also include other
endogenous factors of the CNS.
Fentanyl is an opioid agonist that is used in clinical condi-
tions where there is a risk of hypoxic neurosusceptiblity.
Fentanyl may be neuroprotective against brain ischemic in-
jury and cyclosporin A. Frey reported that fentanyl protects
against some types of brain injury (5).
Therefore, whether or not fentanyl has an influence on the
common side effects of cyclosporin A-inducing seizures and
the neuroprotective effects on cyclosporin A neurotoxicity is
the main focus of this study. 
MATERIALS AND METHODS
Sprague-Dawley rats (14-21 days) weighing 28.7-49.2 g
were used. The animals were kept in groups with their moth-
ers at room temperature with access to food and tap water ad
libitum.
ByungJoon Choi, KyungTai Whang
Department of Pediatrics, Kangnam St. Mary’ s 
Hospital, Catholic University Medical College,
Seoul, Korea
Address for correspondence
ByungJoon Choi, M.D.
Department of Pediatrics, Kangnam St. Mary’ s 
Hospital, 505 Banpo-dong, Seocho-gu, Seoul 
137-040, Korea
Tel : +82.2-590-1472, Fax : +82.2-537-4544
E-mail : choibj@cmc.cuk.ac.kr
96
J Korean Med Sci 2002; 17: 96-102
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Change of Hyperexcitability of Hippocampus by Cyclosporin A and
Its Modulatory Action by Fentanyl
Cyclosporin A is used to treat patients with immune-mediated diseases, chronic
diseases requiring organ transplantation, or malignancies. These conditions often
require higher cyclosporin A doses, which may be toxic to the central nervous
system. Fentanyl is also used in clinical conditions that have a risk of hypoxic
neurosusceptiblity, which suggests that the drug may be a neuroprotective ago-
nist against brain ischemic injury. Fentanyl is an opioid agonist and appears to
play an important role in regulating the excitability of the hippocampus under elec-
troconvulsion. In this study, the effects of fentanyl on modulating cyclosporin A-
induced neurotoxicity was investigated. Treatment with 3 M of cyclosporin A
was found to reduce the electroconvulsive activity threshold. Fifty ng/mL of fen-
tanyl reduced the electroconvulsive activity, and 1 M of DAGO ([D-Ala2, N-Me-
Phe4, Gly-ol]-enkephalin) also decreased the electroconvulsive activity. Fifty ng/
mL of fentanyl was also found to reduce cyclosporin A-induced electroconvul-
sive activity. Although cyclosporin A neurotoxicity may be observed in various
conditions, the opioid effect of neuroprotection may be involved in an interrelat-
ed mechanism. The exogenous opioid agonist suppressed cyclosporin A-induced
electroconvulsive activity. Furthermore, there may be a functional anticonvulsant
effect on cyclosporin A-induced neurotoxicity with an increased opioid agonist
concentration. 
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Prior to decapitation, the animals were anesthetized with
halothane. The whole brains were carefully and rapidly re-
moved, the blood was rinsed off, and placed in a cold oxy-
genated artificial cerebrospinal fluid (ACSF) containing (in
mM): NaCl 120; KCl 3.3; NaH2PO4 1.23; MgSO4 0.9;
NaHCO3 25; CaCl2 1.3; and dextrose 10 under humidified
gas (95% O2, 5% CO2) for 30-45 sec. The pH of ACSF was
7.3-7.4 and the osmolarity was 315-325 mOsm/kg. Subse-
quently, the brain was placed on filter paper and dissected.
The left-side of the brains were placed in clean oxygenated
cold ACSF and the right-side of the brains were placed on
the tissue chopper (Mc Ilwain). The first three hippocampal
slices were discarded and the next 3-8 slices were collected
(650  m in thickness). The slices were placed in a chamber
at room temperature and superfused with oxygenated ACSF.
After equilibration for at least 1-hr incubation with the un-
disturbed superfusion, the extracellular recordings were start-
ed. The slices were placed on a nylon mesh in an incubation
well at 29.5-30.5℃under humidified gas, then perfused
with ACSF at a rate of 3.5-4 mL/min. 
The hippocampal slices were stimulated with a platinum-
coated tungsten bipolar stimulation electrode (A-M Systems)
by single shock pulses of 0.1-msec duration with 60 Hz, for
a total of 2-sec duration, every 10 min (Grass S88 Stimulator).
The recording electrode with a single barrel glass microelec-
trode with a thin wall diameter of 1.5×1.12 mm (A-M sys-
tems) filled with 3M NaCl was placed in the dentate gyrus
(Duo 773 electrometer, World Precision Instrument). 
Prior to exposure to the drugs, the slices were placed in a
stable baseline environment for at least 15 min using the
ground to control artifacts and the response was observed in
an oscilloscope (Nicolet 410, Nicolet Instrument Corpora-
tion). The recording electrode was subsequently placed in
the pyramidal layer of the CA1 region under visual control.
The continued control of the ACSF was recorded for every
10-min electric stimulation, for at least 60 min, 6 times. The
slices were stimulated in conditions of the above drug-induced
conditions, every 10-min, at least eight times. In the 50 ng/
mL fentanyl-treatment experiment after applying 3  M of
cyclosporin A, 50 ng/mL of a fentanyl-containing solution
was perfused immediately after finishing at least eight stim-
ulations every 10 min with 3  M of cyclosporin A. In the
50 ng/mL fentanyl-treatment experiment, 50 ng/mL of a
fentanyl-containing solution were perfused immediately after
finishing at least six stimulations of the control, which was
stimulated every 10 min at least eight times. Subsequently,
10  M of a naloxone-containing solution was perfused and
stimulated every 10 min at least eight times. In the 1  M of
DAGO ([D-Ala2, N-Me-Phe4, Gly-ol]-enkephalin)-treatment
experiment, 1  M of a DAGO-containing solution was per-
fused immediately after finishing at least six stimulations of
the control, which was stimulated every 10 min at least eight
times. Thereafter, 1  M of a CTAP-containing solution was
perfused and stimulated every 10 min at least eight times.
The frequency and duration of the electroconvulsive acti-
vities were then examined eight times, and the mean of 8
observations were obtained. Although five to eight slices were
obtained from one rat, only one slice result from one rat in
the experiments containing cyclosporin A was selected. This
is because the first 3 slices were also discarded in order to ob-
tain stable results. The slices were usually not suitable for
recording the drug effect  after 10 hr, and slices showing the
cyclosporin A-induced continuous electroconvulsive activity
after 6 stimulation with no resting phase were excluded. The
frequency, duration, and the latency of onset observing dif-
ferent types of electrical activity under each experimental
condition were analyzed by a Student’ s t-test and using the
advisor wizard of Sigmastat. Quantitative variables are ex-
pressed as a mean±SD.
RESULTS
The effect on the ictal and interictal activity of the elec-
troconvulsive activities on the hippocampus by fentanyl
treatment after cyclosporin A
Treatment with 3  M of cyclosporin A increased both the
duration and frequency of the electroconvulsive activity (Fig.
1A2). The mean duration and frequency of 3  M of cyclo-
sporin A-induced ictal activity were 35.5±1.4 sec (Fig. 1B)
(n=15) and 133.0±17.9 (Fig. 1C) (n=15), respectively. There
were significant differences in the duration and frequency
between the 3  M cyclosporin A-induced ictal activity and
the control group. 3  M of cyclosporin A on the hippocam-
pal slices showed interictal activity (Fig. 2A2). The mean
duration and frequency in the 3  M of cyclosporin A-induced
interictal activity were 116.4±44.4 sec (Fig. 2B) (n=9) and
63.6±35.8 (Fig. 2C) (n=9), respectively. There was no sig-
nificant difference in the duration and frequency of onset
between the 3  M of cyclosporin A-induced interictal activ-
ity and the control group showing interictal activity. The
mean latency time of onset was 166.2±29.8 sec (Fig. 2D)
(n=9). There was a significant difference in latency between
the 3  M of cyclosporin A-induced interictal activity and
the control showing interictal activity. However, there were
nine 3  M of cyclosporin A-induced slices showing interic-
tal activity.
Treatment with 50 ng/mL fentanyl shortened the dura-
tion and decreased the frequency of the 3  M cyclosporin
A-induced ictal activity (Fig. 1A3). The mean duration and
frequency of the elecrtoconvulsive activity of the 50 ng/mL
fentanyl-induced ictal activity were 24.9±1.9 sec (Fig. 1B)
(n=4) and 90.3±16.5 (Fig. 1C) (n=4), respectively. There
were significant differences in both the duration and frequen-
cy between the 50 ng/mL fentanyl-induced and the 3  M
cyclosporin A-induced ictal activity.
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slices showed the interictal activity (Fig. 2A3) (n=4). The
mean duration and frequency of the 50 ng/mL fentanyl-in-
duced interictal activity were 405.3±46.6 sec (Fig. 2B) (n=
4) and 218.0±100.5 (Fig. 2C) (n=4), respectively. There
were significant differences in both the duration the frequen-
cy between the 50 ng/mL fentanyl-induced interictal activi-
ty and the 3  M cyclosporin A-induced interictal activity.
The mean duration of latency was 36.0±11.9 sec (Fig. 2D)
(n=4), and there was a significant difference in the latency
between the 50ng/mL fentanyl-induced interictal activity
and the 3  M cyclosporin A-induced interictal activity. Four
slices with the 50 ng/mL fentanyl-treatment showing inter-
ictal activity was significantly different from that of the cyclo-
sporin A-induced slices showing interictal activity. 
The effects of 50 ng/mL of fentanyl on the electrocon-
vulsive ictal and interictal activity in the control hippo-
campal slices
Treatment with 50 ng/mL of fentanyl shortened both the
duration and decreased the frequency of electroconvulsive
ictal activity in the control hippocampal slices (Fig. 3A2).
The mean duration and frequency of the 50 ng/mL fentanyl-
induced electroconvulsive activity were 23.1±2.4 sec (Fig.
3B) (n=10) and 85.9±8.1 (Fig. 3C) (n=7), respectively. There
was a significant difference in duration between the 50 ng/
mL fentanyl-induced ictal activity and the control, but there
was no significant difference between the two groups. 
50 ng/mL fentanyl on the control hippocampal slices show-
ed the interictal activity (Fig. 4D2) and the mean duration
and frequency of the 50 ng/mL fentanyl-induced interictal
activity were 518.5±64.0 sec (Fig. 4A) (n=5), and 132.0
±14.0 (Fig. 4B) (n=5), respectively. There were significant
differences in both the duration and frequency between the
50 ng/mL fentanyl-induced interictal activity and the con-
Fig. 1. Effect of fentanyl on cyclosporin A-induced electroconvulsive ictal activity. (A1) Control electroconvulsive ictal activity. (A2) 3
M of cyclosporin A increased the electroconvulsive ictal activity. (A3) 50 ng/mL of fentanyl decrease the cyclosporin A-induced
electroconvulsive activity. (B) 3 M of cyclosporin A prolong the duration of the electroconvulsive ictal activity and 50 ng/mL of fentanyl
shorten the duration of 3 M of cyclosporin A-induced ictal activity. (C) 3 M of cyclosporin A increase the frequency of the electro-
convulsive ictal activity and 50 ng/mL of fentanyl decrease the frequency of 3 M of cyclosporin A-induced electroconvulsive activity.
*p<0.05.
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Fig. 2. Effect of fentanyl on cyclosporin A-induced electroconvul-
sive interictal activity. (A1) Control electroconvulsive interictal
activity. (A2) 3 M of cyclosporin A show some electroconvul-
sive interictal activity. (A3) 50 ng/mL of fentanyl show numerous
electroconvulsive interictal activity. (B) 3 M of cyclosporin A
prolong the duration of control electroconvulsive interictal activi-
ty and 50 ng/mL of fentanyl show a great increase of duration of
3 M of cyclosporin-induced interictal activity. (C) 3 M of cy-
closporin A increase the frequency of control electroconvulsive
interictal activity and 50 ng/mL of fentanyl show a great increase
of frequency of 3 M of cyclosporin A-induced electroconvul-
sive interictal activity. (D) Latency time of onset of interictal activi-
ty in 3 M of cyclosporin A and 50 ng/mL of fentanyl is greatly
shortened compared to that in the control. The numbers of slices
showing the interictal activity are not significantly different be-
tween the control and 3 M of cyclosporin A-induced groups,
but are significantly different between 3 M of cyclosporin A-
and 50 ng/mL of fentanyl-induced groups. *p<0.05.
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trol interictal activity. The mean latency in the 50 ng/mL
fentanyl-induced groups was 143.0±11.3 sec (Fig. 4C) (n=5),
and there was a significant difference in the latency between
the 50 ng/mL fentanyl-induced interictal activity and the
control hippocampal slices showing interictal activity. Five
slices with 50 ng/mL of fentanyl-treatment showing inter-
ictal activity were significantly different than the control
hippocampal slices showing interictal activity. The interictal
activity from 50 ng/mL of fentanyl on the control hippocam-
pal slices was reversed by 10  M naloxone (Fig. 4D3).
The effects of 1 M of DAGO on ictal and interictal acti-
vity in hippocampal slices  
1  M DAGO shortened the duration of ictal activity in the
hippocampal slices and decreased the frequency (Fig. 5A2).
The mean duration and frequency of the 1  M of DAGO-
induced electroconvulsive activity were 12.7±2.8 sec (Fig.
5B) (n=7) and 87.3±11.1 (Fig. 5C) (n=7), respectively.
There were significant differences in both the duration and
frequency between the 1  M DAGO-induced ictal activity
and the control hippocampal slices.
1 M of DAGO perfusion into the hippocampal slices show-
ed interictal activity (Fig. 6D2) and the mean duration and
frequency of the 1  M DAGO-induced interictal activity
were 464.6±42.5 sec (Fig. 6A) (n=5) and 64.2±23.0 (Fig.
6B) (n=5), respectively. There were significant differences in
both the duration and frequency between the 1  M DAGO-
induced interictal activity and the control hippocampal slices
showing interictal activity. The mean latency in the 1  M
DAGO-induced slices was 28.4±9.4 sec (Fig. 6C) (n=5),
and there was a significant difference in the latency between
the 1  M DAGO-induced interictal activity and the control
hippocampal slices showing interictal activity. The number
of 1  M DAGO-induced slices showing interictal activity
differed significantly from the control hippocampal slices
showing interictal activity. The interictal activity of hippocam-
pal slices treated with 1  M DAGO was reversed by 1  M
of D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 (CTAP)
(Fig. 6D3).
Fig. 3. Effect of fentanyl on electroconvulsive ictal activity of control hippocampal slices. (A1) Control electroconvulsive ictal activity. (A2)
50 ng/mL of fentanyl show a decrease of control electroconvulsive ictal activity. (B) 50 ng/mL of fentanyl shorten the duration of control
electroconvulsive ictal activity. (C) 50 ng/mL of fentanyl decrease the frequency of control electroconvulsive ictal activity. *p<0.05.
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Fig. 4. Effect of fentanyl on control electroconvulsive interictal ac-
tivity. (A) 50 ng/mL of fentanyl increase duration of control electro-
convulsive interictal activity. (B) 50 ng/mL of fentanyl increase fre-
quency of control electroconvulsive interictal activity. (C) Latent
time of onset of interictal activity in 50 ng/mL of fentanyl-induced
group is greatly shortened compared to that in the control. The
numbers of slices showing the interictal activity are significantly
different between control and 50 ng/mL of fentanyl-induced groups.
(D1) Control hippocampal slices show no interictal activity. (D2)
50 ng/mL of fentanyl show interictal activity. (D3) The interictal
activity by 50 ng/mL fentanyl is reversed by 10 M of naloxone.
*p<0.05.
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DISCUSSION
This study showed that 3  M cyclosporin A elongated the
duration of electroconvulsive activity on a hippocampal slice
under 1.3 mM of calcium, and decreased the electroconvul-
sive threshold. An in vivo study of electroshock-induced
seizure suggested that cyclosporin A lowers the seizure thre-
shold (8). However, another in vitro study did not show any
cyclosporin A neurotoxicity (9) whereas an in vitro cyclo-
sporin A model showed that the cyclosporin A-induced elec-
troconvulsive activity with hypomagnesemia (10). Because
the in vitro model is only a reflection of the applied cyclo-
sporin A effects under ACSF without other systemic and
metabolic interplay, our results reflected the effect of the low
calcium level. Both hypocalcemia and hypomagnesemia cause
cyclosporin A toxicity (1, 11). As suggested by the presence
of many clinical conditions associated with cyclosporin A
neurotoxicity, its toxicity is markedly exaggerated under
certain concurrent factors, including hypocalcemia. 
The present study showed that 1  M cyclosporin A caused
no changes in the convulsion threshold, while 3  M of cyclo-
sporin A decreased the electroconvulsive threshold. Although
cyclosporin A neurotoxicity cannot be predicted in a dose-
dependent manner, it is generally associated with serum con-
centrations higher than 1  M (12-14). These cyclosporin A
serum concentrations at the equilibrium status are trough
levels; a higher peak level may be achieved temporarily even
in the same patient under certain conditions (2). Moreover,
cyclosporin A is lipophilic and has a high affinity to cyclo-
philin and calcineurin, which are highly concentrated in cor-
tical neurons (15, 16). Cyclosporin A also has a high affinity
for lipoproteins including low-density lipids and its active
cellular uptake via the low-density lipoprotein receptors may
have a concentrating effect (17). As a result, the higher cyclo-
sporin A concentration showed an increasing likelihood of
neurotoxicity (18). Cyclosporin A exhibited concentration-
dependent damage: neuronal damage occurred from 5 to 30
M cyclosporin A; astrocyte damage occurred from 5 to 60
M cyclosporin A; and oligodendrocyte damage occurred
from 1 to 15  M cyclosporin A (18). In these experiments,
a higher dose of cyclosporin A might have increased the like-
Fig. 5. Effect of DAGO on electroconvulsive ictal activity of control hippocampal slices. (A1) Control electroconvulsive ictal activity. (A2)
1 M of DAGO show a decrease of control electroconvulsive ictal activity. (B) 1 M of DAGO shorten the duration of control electrocon-
vulsive ictal activity. (C) 1 M of DAGO decrease the frequency of control electroconvulsive ictal activity. *p<0.05.
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Fig. 6. Effect of DAGO on control electroconvulsive interictal ac-
tivity. (A) 1 M of DAGO increase duration of control electrocon-
vulsive interictal activity. (B) 1 M of DAGO increase frequency
of control electroconvulsive interictal activity. (C) Latency time
of onset of interictal activity in 1 M of DAGO is greatly shortened
compared to that in the control. The numbers of slices showing
the interictal acti-vity are significantly different between control
and 1 M of DAGO-induced groups. (D1) Control hippocampal
slices show no interictal activity. (D2) 1  M of DAGO show an
interictal activity. (D3) The interictal activity by 1 M of DAGO is
re-versed by 1 M of CTAP. *p<0.05.
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lihood of detecting cyclosporin A neurotoxicity.
It has been reported that various opioid agonists increase
the seizure threshold and have anticonvulsant effects (19).
Opioids have a protective role against seizure activity by cy-
closporin A that is mediated by the opioid receptors, and the
mu and delta opioid agonists have an anticonvulsant effect
(20, 21). Fentanyl is an opioid agonist bearing activity at the
mu and delta agonists with greater activity at the former. The
anticonvulsant effect of fentanyl and enhanced anticonvul-
sant effect of phenytoin and phenobarbitone by fentanyl have
been reported (6). 
This study demonstrated that 50 ng/mL of fentanyl short-
ened the cyclosporin A-induced electroconvulsive activity
and increased the threshold of electroconvulsive activity.
Fentanyl may play an important role in regulating the hip-
pocampal excitability, especially in a hippocampus under
seizure. These findings show that fentanyl has a protective
role against cyclosporin A-induced electroconvulsive activi-
ty and the cyclosporin A-induced electroconvulsive activity
were also modulated by fentanyl. The anticonvulsant action
of fentanyl on the cyclosporin A-induced electroconvulsive
activity may be mediated primarily by the mu or delta opi-
oid receptors. The potential importance of activating opioid
substances by seizures usually involves the modulation and
regulation of seizure (22) and the most effective anticonvul-
sant appears to act at the mu and delta binding sites (23).
Opioid-induced seizure protection is related to endogenous
opioid substances and is also selectively mediated by the mu
and delta receptors (19).
The mu opioid receptor agonists increase the seizure thresh-
old and have anticonvulsant activity (24). Opioid receptors
subtypes are localized in the rat hippocampus (25) and  the
number of opioid substances in the hippocampus are great-
ly changed by seizure (26). Fentanyl and DAGO were then
used to examine the electroconvulsive activity, especially in
the hippocampus. The results showed a shortening of the
electroconvulsive activity duration and an elevated electro-
convulsive threshold after fentanyl, as has been reported else-
where (5), and anticonvulsant effect of DAGO, which has also
been reported (19). The shortening induced by both fentanyl
and DAGO was reversed by 10  M of naloxone and 1  M
of the highly specific mu receptor antagonist CTAP (D-Phe-
Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2). This suggests the
anticonvulsant effect of fentanyl and DAGO is mediated by
the opioid receptors and the effect is stronger on mu opioid
receptors.
The interictal activity by fentanyl and DAGO also disap-
peared with a perfusion of 10  M of naloxone and 1  M of
CTAP, respectively. Fentanyl and DAGO may act postictally
on the spontaneous arrest of seizures and modulate postictal
inhibition. There is an inherent ability of a seizure to inhib-
it the recurrence of subsequent seizure episodes, and this opi-
oid is included in post-seizure inhibition (7).
Although cyclosporin A neurotoxicity can be influenced by
various factors, the opioid effect of neuroprotection is involved
in the interrelated mechanism. These exogenous opioids sup-
press the cyclosporin A-induced electroconvulsive activity,
and with an increased level of opioids, there may be a func-
tional anticonvulsant effect on cyclosporin A-induced neu-
rotoxicity. These results suggest that opioid substances may
play a role in the pathogenesis of cyclosporin A-induced neu-
rotoxicity and these results may be a positive clue to the rela-
tionship between cyclosporin A-induced neurotoxicity and
the opioid system.
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